ElevateBio is a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise to advance the cell and gene therapy industry. The company's integrated ecosystem of technologies and capabilities enables the discovery, development, manufacturing, and commercialization of a broad spectrum of cell and gene therapies and regenerative medicines.

Clare Murray

ElevateBio

BioEclipse Therapeutics focuses on developing immunotherapies for cancer treatment, specifically targeting solid tumors and enhancing patient responses through combined therapies involving immune cells and oncolytic viruses. The company is currently advancing its product, CRX100, through clinical trials.

BioEclipse Therapeutics

CM Life Sciences is involved in biotechnology and healthcare investments.

CM Life Sciences

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Life Edit Therapeutics

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, ElevateBio BaseCamp is a purpose-built, technology-enabled manufacturing platform offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities for viral vectors, RNA, and cell therapy production. Through BaseCamp, its expanding footprint, and its next-generation enabling technologies, ElevateBio is rapidly growing its collaborations with industry partners while also selectively developing its own portfolio of cellular and genetic medicines. 

ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

AlloVir

Samsara BioCapital

Surveyor Capital

Vertex Ventures

Invus

ITOCHU Corporation

Redmile Group

EDBI

Emerson Collective

F2 Ventures

Fidelity Management and Research Company

Woodline Partners

Matrix Capital Management

Novo Nordisk

Fidelity

Exciting news!  Life Edit Therapeutics Chief Scientific Officer, Tedd Elich, was recently highlighted in BioPharm International in the feature, "Milestone Approval to Steady Stream, Gene Editing Revs Up." Gain valuable insights into the future of gene editing, technology advancements, and more. Access the full article in the comments below.

Our Life Edit gene editing business offers diverse tools for unlimited gene editing. This platform boasts the ability to make "any edit anywhere" - from small deletions and insertions to rewriting the DNA sequence – and delivers versatility and flexibility. 

Learn more about partnering with us at https://lnkd.in/gMf9yFkv

#ElevateBio #InnovateAtElevate #GeneticMedicine

No matter where you are with your development journey, our LentiPeak™ platform can help you reach your next milestone faster.

Our proprietary lentiviral vector (LVV) platform is suspension-based and scalable to meet your needs, offering streamlined tech transfers, control strategies for risk mitigation and proven performance with CAR and TCR constructs at multiple production scales.

Take the first step towards elevating our future together: https://lnkd.in/ed8fRD-F.

#GeneManufacturing #ElevateBio

Frank Bugg, our Global Head of BaseCamp Operations will discuss BaseCamp's capabilities in supporting partnerships across research, discovery, analytical development, and more as part of the Outsourced Pharma Capacity Update series on February 15 at 10 am EST. 

Register at https://lnkd.in/eEMjUqyS. 

#ElevateBio #Biotech 

We guide our partners through their journey from concept to commercialization, or at any stage in between. BaseCamp, our cGMP manufacturing facility, is equipped for the full product lifecycle; we have expertise in developing and scaling processes for cell therapies and viral vectors, and we offer analytical and enabling services, too. 
Our proprietary lentiviral vector platform–LentiPeak™–can be fully customized to fit partners’ needs. 

Learn more about the benefits of a strategic relationship with ElevateBio: https://lnkd.in/evp85Xpk.

#BaseCamp #CellTherapy #GeneTherapy


Metric
Company Name	ElevateBio	BioEclipse Therapeutics	CM Life Sciences	Therini Bio
Symbol
MSH ID	BIO:ELEVATE	COM:BIOECLIPSE	COM:CMLIFESCIENCESSPAC	COM:THERINIBIO
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Financial Services & Finance	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Investment Management	Biotechnology
Country	US	US	US	US
Stage	Series D
Employee Count	462
Website	elevate.bio	bioeclipse.com	cmlifesciencesspac.com	therinibio.com
LinkedIn	elevatebio			therinibio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	7.15K
Web Traffic Growth	-0.51
Valuation
Raised Capital	401M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIO:ELEVATE

ElevateBio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue